In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Pfizer (PFE – Research Report), with a ...

Whatever the case, the fundamentals of a politically supportive backdrop for Novavax’s traditional approach to vaccines could easily boost NVAX stock under Trump’s second administration. With that in ...

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, today announced an expansion of their partnership with Pfizer. The parties will launch a new ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

A new report published in the journal Communications Medicine suggests Pfizer’s (PFE) Paxlovid may help some long Covid patients, but which ...

A woman in the U.S has become the center of medical intrigue after experiencing dramatic breast growth after taking Pfizer COVID-19 vaccine.

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

The increases are to list prices, which do not include rebates to pharmacy benefit managers and other discounts.

Sangamo Therapeutics' (SGMO) shares were sinking intraday Tuesday after the company said its partner Pfizer (PFE) decided not to proceed with further development of a new gene therapy to treat ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.